問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
李潤川
下載
2018-11-30 - 2025-12-31
Condition/Disease
Locoregional Hepatocellular Carcinoma
Test Drug
DURVALUMAB (IMFINZI, MEDI4736)
Participate Sites10Sites
Recruiting9Sites
Digestive System Department
2021-07-01 - 2024-07-26
Participate Sites5Sites
Not yet recruiting2Sites
Recruiting3Sites
2021-10-01 - 2026-06-30
Recruiting5Sites
2018-12-06 - 2025-12-31
Neuroendocrine Tumors
CVM-1118
Participate Sites8Sites
Recruiting4Sites
Terminated3Sites
Division of Hematology & Oncology
未分科
2013-08-12 - 2026-03-17
Participate Sites4Sites
2021-12-30 - 2025-12-31
Participate Sites6Sites
Recruiting6Sites
2021-12-01 - 2024-12-31
Participate Sites2Sites
Recruiting2Sites
2021-10-01 - 2027-06-30
Participate Sites16Sites
Recruiting13Sites
2019-09-01 - 2025-12-31
Biliary Tract Carcinoma
Pembrolizumab (MK-3475)
Participate Sites7Sites
Recruiting7Sites
2021-01-01 - 2026-12-31
Participate Sites3Sites
全部
